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Abstract 
Objective To examine in a nationally representative sample (a) the differential association of specific 
anxiety and depressive disorders defined according to DSM-IV with pain disorder (PD) and pain 
symptoms, and (b) whether pain-associated anxiety and depressive disorders and their comorbidity 
have different implications in terms of impairment, disability, health care utilization, and substance 
use.  
Method A nationally representative community study was conducted in Germany. Symptoms, 
syndromes and diagnoses of mental disorders, and pain were assessed in N = 4,181 participants aged 
18–65 years using the DSMIV/ M-CIDI.  
Results Logistic regressions revealed that pain is associated with both specific anxiety and depressive 
disorders, with increasing significant odds ratios (OR) for medically explained pain symptoms (EPS; 
OR range: 1.9–2.0), to unexplained pain symptoms (UPS; OR range: 2.4–7.3), to PD (OR range: 3.3–
14.8). PD and UPS persistently showed associations after adjusting for comorbid other anxiety and 
depressive disorders and physical illnesses. All types of pain, particularly PD/UPS, are associated with 
decreased quality of life, greater impairment in role functioning, disability, health care utilization, and 
substance use. Depressive disorders, even more so anxiety disorders and their comorbidity account for 
a substantial proportion of variance in these functional correlates.  
Conclusions Pain is strongly associated with specific anxiety and depressive disorders. In light of the 
individual and societal burden due to pain, and the demonstrated role of comorbid anxiety or/and 
depression, our results call for further investigation of the underlying mechanisms for this association 
as well as targeted treatments for these comorbidities.  
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Introduction 
 
Pain, anxiety, and depressive disorders are prevalent and burdensome conditions in the 
community [1, 2, 24, 33, 34, 39, 58, 66, 97]. The intimate and reciprocal relationships 
between these conditions have been well documented on a symptomatic (dimensional) level 
[22, 25, 27, 34, 60, 72, 76, 82, 88, 92], as were the clinical-therapeutic implications of these 
relationships for the management of pain syndromes [9, 38, 52, 85]. The nature and the 
implications of such complex associations on the diagnostic level, however, remain unclear 
and understudied. Few studies have systematically examined the relationships between pain 
conditions and specific well-defined DSM-diagnoses [3, 4], especially in non-clinical, 
representative population samples, with most research attention given to depressive disorders 
[18, 21, 33, 52, 59, 69]. Depression was also shown to have a significant impact on disability 
in pain [18, 20]. Regarding anxiety disorders, recent findings from population-based samples 
also indicate associations with pain which seem to be of equal or greater strength compared to 
the pain-depression associations [21, 26, 33, 53, 58, 59, 91]. To our knowledge, no 
population-based study has systematically examined the impact of anxiety disorder 
comorbidity on disability in pain.  
 
Pain as defined by the International Association for the Study of Pain is „an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or 
described in terms of such damage“ [61]. That is, the subjective experience of pain including 
sensory, emotional, behavioural, and cognitive components is not solely due to tissue damage. 
Many pain symptoms remain „medically unexplained“ or „incompletely explained“, i.e., the 
pain cannot be (fully) explained by the presence of general medical condition, by the direct 
effect of an exogenous substance, or by a mental disorder such as anxiety or depression. 
According to a review by Kroenke [48], in the health care system at least one-third of somatic 
symptoms are medically unexplained. There has been extensive debate about the terminology, 
conceptualization, and classification of such medically unexplained conditions [35, 49, 56, 75, 
84, 86]. While in medical routine care, the term „functional syndrome“ is frequently used, the 
DSMIV [5] and ICD-10 [95] classify pain in which psychological factors are judged to have 
an important role in the onset, severity, exacerbation, or maintenance of pain as a 
(somatoform) „pain disorder“. Along with explicit descriptive criteria, this category was 
meant to increase the reliability of assessment, although it is important to note that this 
description remains controversial. The categorization of symptoms to be „medically 
unexplained/somatoform“ can be difficult [49] and theoretically and practically problematic 
[56, 75]. This has led some [49, 56, 75] to suggest simplifying the categorization of pain 
disorder and to use a more appropriate, „etiologically neutral“ terminology for physical 
symptoms including pain. Others [35], however, have underlined the progress and importance 
of research with somatoform diagnoses as mental disorders integrating biological, 
psychological, and social aspects. 
 
Acknowledging the controversy surrounding the conceptualization and terminology of 
„medically unexplained“ pain and „pain disorder“, this paper examines in a large German 
general population sample the differential association of specific anxiety and depressive 
disorders defined according to DSM-IV with pain disorder and pain symptoms. Other than a 
previous report [26], we consider self-reported lifetime medically unexplained and explained 
pain symptoms. Moreover, we will explore whether the pain-associated anxiety and 
depressive disorders and their comorbidity have different implications in terms of impairment, 
disability, health-care utilization, and substance use.  
 
 
Methods 
 
The data presented in this paper come from the German National Health Interview and 
Examination Survey, Mental Health Supplement (GHS-MHS) conducted in 1998/1999. The 
survey was approved by the institutional review board of the Robert Koch Institute (Berlin, 
Germany). All participants provided written informed consent. The aims, design, and methods 
of the survey have been described in more detail elsewhere [40].  
 
Sample 
 
The GHS (core survey) covered a range of medical and social assessments in a multistage, 
stratified, cross-sectional, random sample of the general German population aged 18–79 
years, drawn from population registries (N = 7,124; response rate: 61.5%). The MHS (one of 
several supplements) included a subsample thereof (N = 4,181; conditional response rate: 
87.6%). This subsample can be regarded as representative for the German non-
institutionalized adult population in the age–range of 18–65 years [40]. Older subjects were 
excluded from the MHS due to unsatisfactory psychometric properties of the used diagnostic 
assessment instrument – the Munich Composite International Diagnostic Interview (DIA-
X/M-CIDI) – in older populations [47].  
 
Measures 
 
Assessment of mental disorders 
 
The assessment of mental disorders was based on the computer-assisted version (CAPI) of the 
Munich Composite International Diagnostic Interview (DIA-X/M-CIDI) [99, 101], a modified 
version of the World Health Organization (WHO) CIDI, version 1.2, supplemented by 
questions to cover DSM-IV [4] and ICD-10 criteria [95]. The DIA-X/M-CIDI was 
administered by clinically trained interviewers (psychologists and MDs). Psychometric 
properties of the DIA-X/M-CIDI were found to range from acceptable to very good for all 
diagnoses considered in the current study: the test–retest reliability ranged from kappa = 0.45 
for GAD to 1.00 for panic disorder [99]. Inconsistencies in GAD were mainly due to different 
responses in regard to the 6-month time duration; retest-reliability of the GAD stem question, 
however, was good and in the range of other disorders (kappa = 0.70). Validity of the DSM-
IV/M-CIDI diagnoses compared to independent clinical consensus diagnoses by treating 
physicians was estimated with kappa ranging from 0.50 for somatoform disorder to 0.96 for 
major depressive episode (MDE) [70]. Age-of-onset reliability estimates are also established 
with intra class coefficients ranging from 0.45 for specific phobia environmental-subtype to 
0.97 for GAD and MDE [99, 100].  
 
Pain disorder The diagnosis of (somatoform) pain disorder was generated by using the 
standard DSM-IV/MCIDI algorithms [101]. In the somatoform disorders section of the DIA-
X/M-CIDI, the presence of the following painful conditions is initially assessed from the 
respondents on a lifetime basis: abdominal pain, back pain, joint pain, limb pain, chest pain, 
headache, excessively painful menstruation, rectal and genital pain, and other pain. For 
commonly experienced pain types (belly pain, back pain, headache, and painful menstruation) 
the threshold for positive endorsement was increased by asking whether the respondent has 
ever had „a lot of trouble“ with this pain. Whenever the respondent acknowledged having 
experienced at least one of these pain types, the interviewer enters a standardized complex set 
of probe questions (see Fig. 1) to evaluate the nature of the complaint [73, 96].  
 
The probe questions start with establishing clinical severity/significance. A symptom is 
considered „clinically significant“ if the symptom prompts help-seeking from a medical 
doctor or another health professional, the use of medication more than once for it, or if the 
symptom interfered a lot with life or activities (criterion A). For headaches and painful 
menstruation, positive endorsement of medication use more than once was not considered as 
sufficient for establishing clinical significance. Here, respondents must have additionally 
reported medication prescription by a doctor (pertaining to headaches and painful 
menstruation), or the use of prescription-free medication at least three times a week 
(pertaining to headaches) [101].  
 
Next, further probe questions establish from the respondents whether there are any physical or 
substancerelated factors that explain the occurrence of the pain symptom („medically 
explained“ pain). As shown in Fig. 1, there are several paths with various questions to be 
answered before a symptom is considered to be „medically unexplained“ (somatoform). Only 
when the symptom, per respondents’ report, was not or not always explained by medical 
diagnosis (e.g., doctor’s diagnosis of migraine for headaches) or injury, or the use of 
medication, drugs or alcohol, the symptom is rated as „medically unexplained“ and – 
consistent with the DSM-IV stipulation – counted towards a diagnosis of somatoform pain 
disorder (criterion C; note that the controversial ‘psychological factors’ criterion [35, 49, 56, 
75, 84, 86] is particularly difficult to assess with a standardized instrument in an 
epidemiological study [compare 30]).  
 
If at least one painful condition was found to be present as clinically significant and medically 
unexplained (somatoform), further questions were asked to assess impairment and distress 
(DSM criterion B) as follows [4]: „Did the pain keep you from working or seeing friends or 
relatives for 6 months or more?“, „How much did the pain interfere with your life and daily 
activities?“ If the respondent acknowledged either impairment OR a lot interference with life, 
then the DSM-IV diagnosis of pain disorder was given.  
 
DSM criterion D (the symptom is not intentionally produced or feigned) was not assessed by 
the DIA-X/M-CIDI. The exclusion criterion E (the pain is not better accounted for by a mood, 
anxiety, or psychotic disorder) will be considered by providing the proportion of respondents 
who reported that their physician attributed their pain to „anxiety, panic attacks, or 
depression“.  
 
Keeping the controversy regarding somatoform pain and pain disorder in mind, we consider 
in the current paper the diagnosis of (somatoform) pain disorder (PD) as based on 
respondents’ self-reports and DIA-X/M-CIDI algorithms. In addition, we included the 
following pain categories below this diagnostic threshold: (a) at least one clinically 
significant, unexplained (somatoform) pain symptom (UPS) but no PD and (b) at least one 
clinically significant, explained (non-somatoform) pain symptom (EPS) but no unexplained 
(somatoform) pain symptoms. Individuals with no clinically significant pain symptoms (no 
PS; includes individuals without any pain and individuals with non-significant pain) were 
used as reference group.  
 
Throughout our paper, we report on self-reported lifetime occurrence of pain, because the 
age-of-recency of pain – and therefore 12-month status – was only assessed among 
individuals with any medically unexplained (somatoform) pain.  
 
Depressive and anxiety disorders Diagnoses of depressive disorders (major depression and 
dysthymia) and anxiety disorders (specific phobia, social phobia, agoraphobia, phobia not 
otherwise specified (NOS), generalized anxiety disorder (GAD), panic disorder, and obsessive 
compulsive disorder (OCD) were also assessed using the DIA-X/M-CIDI and the DSM-IV 
algorithms [101]. Because lifetime information is not available for all the anxiety disorders, 
we refer to 12-month anxiety and depressive disorders throughout the paper.  
 
Substance use and substance use disorders Substance use and substance use disorders were 
also assessed using the DIA-X/M-CIDI. In the current paper, the following dichotomous 
variables for substance use were considered for analyses on correlates: during the past year, 
(a) harmful alcohol use (weekly alcohol use, 20/40 g alcohol per drinking day for 
women/men), (b) daily smoking over a period of at least 4 weeks, and (c) any illicit 
medication/ substance use (including: cannabis, stimulants, sedatives/ hypnotics/anxiolytics, 
opiates, cocaine, PCP, psychodelics, inhalants, „other“ substances).  
 
Assessment of somatic disorders 
 
A self-report questionnaire was used to asses the presence of 44 physical diagnoses from 16 
disease groups (e.g., cardiac diseases, diabetes, cancer, allergies (see [40]). Taking this 
information into account, study doctors conducted a computer-assisted standardized interview 
and established lifetime, 12-month and point prevalences of physical disorders. In this paper, 
we use a variable containing the number of physical disorders during the past 12 months 
(range 0–9) as control variable.  
 
Other measures 
 
Assessment of health related quality of life The German version [14, 94] of the well-validated 
self-report Medical Outcome Study 36-item short form (SF-36) [13, 15, 23, 37, 57, 83] was 
used to assess eight health concepts for the past 30 days. Principal component analysis has 
identified two dimensions of the SF-36: a physical component score and a mental component 
score [93]. These scores were standardized to M = 50 and SD = 10.  
 
Assessment of disability Similar to previous surveys [e.g., 74], past 4-week disability was 
examined by the selfreported number of days being unable to carry out usual daily activities 
(school, study, work, household) (1) due to mental (emotional, psychosomatic, or psychiatric) 
problems, (2) due to alcohol, drug or medication use, and (3) due to physical problems and 
illnesses. The number of overall disability days was generated by counting a full day for each 
day a person was totally unable to carry out usual activities and adding a half-day for each day 
a person was partly disabled to carry out usual activities. This summary variable reflects the 
number of disability days in the past month ranging from 0 to 28 days (higher summary 
scores were set to 28 days).  
 
Assessment of health care utilization The assessment of health care utilization included self-
reported data on the number of (1) general practice visits, (2) consultations with specialists 
(12 domains, including neurologists, psychiatrists, and psychologists), and (3) days spent in 
hospital within the past 12 months.    
 
Statistical analyses 
 
Statistical analyses were done with the STATA software package, release 10.0 [81]. Data (%, 
M, SD, and regressions/ ratios) were weighted for age, gender, region and screening status in 
order to address different sampling probabilities and systematic non-response [40]; number of 
cases is reported unweighted (N, n).  
 
Logistic regression analyses were used to quantify associations [odds ratios, OR; with 95% 
confidence intervals (CI), and P values] between PD, UPS, and EPS on the one hand and 
specific depressive disorders and anxiety disorders on the other (crude association, controlled 
for age and gender only). To test whether those associations persist even after adjusting for 
comorbid conditions, first anxiety and depressive disorders were included as control variables 
in the regressions, and then additionally a variable containing the number of physical 
disorders.  
 
Correlates of pain (health related quality of life, disability days, health care utilization and 
substance use) were also assessed by regression analyses. For dichotomous outcomes (i.e., 
substance use), associations were assessed with odds ratios (ORs) from logistic regressions. 
Associations with count variables (i.e., number of disability days, number of health care 
visits) were assessed with mean ratios (MRs) from negative binomial regressions [50]. These 
regressions are useful for positively skewed distributions of infrequent events and the 
associated mean ratios reflect the change in the expected count of a particular event per unit 
increase in the covariate. Mean ratios from gamma regressions were used for gamma-
distributed SF-36 outcomes. A significant ratio of <1 indicates a decrease of health related 
quality of life. First, associations were assessed controlling for age and gender only. In order 
to estimate the degree to which comorbid anxiety or/and depressive disorders account for 
these associations, the analyses were rerun while additionally controlling for (a) anxiety 
disorders, (b) depressive disorders, and (c) anxiety and depressive disorders. The relative 
change in association between pain and predictors was then calculated.1 The results reflect the 
percentage change in the association between pain and the correlates due to adjustment of 
anxiety (A), depressive (D), or anxiety and depressive disorders (A + D). Negative 
percentages reflect smaller increase in disability, health care utilization and substance use, 
while positive percentages reflect smaller decrease in health related quality of life.  
 
 
Results 
 
Prevalence and comorbidity of pain, anxiety disorders and depressive disorders 
 
 Four out of five individuals (81.2%) in the general population experienced at least one 
significant pain symptom in their lifetime (Fig. 2). The majority of affected individuals had 
EPS only (55.2%), with the remaining reporting at least one UPS (44.8%). Among those with 
UPS, one-third met criteria for PD (35.1%). Back pain (40.5%), joint pain (32.5%) and 
abdominal pain (16.1%) were the three most commonly experienced significant explained 
pain types; among unexplained pain symptoms headache (12.7%), back pain (8.5%), and 
abdominal pain (8.3%) were reported most frequently.  
 
Overall, lifetime prevalence rates for mutually exclusive diagnostic pain categories were 
12.7% for PD, 23.7% for UPS (no PD), and 44.8% for EPS (no UPS/PD). The mean number 
of unexplained pain symptoms was 1.7 (SD = 1.0, range 1–7) in the PD group and 1.5 (SD = 
0.8, range: 1–6) in the UPS group; the mean number of explained pain symptoms among 
individuals with PD, UPS, and EPS were 1.8 (SD = 1.6, range 0–7), 1.4 (SD = 1.3, range: 
range 0–6), and 2.0 (SD = 1.2, range 1–8), respectively. The proportion of individuals 
reporting unexplained pain symptoms only (no significant explained pain symptoms) was 
20.3% in the PD and 30.2% in the UPS group. Of note, 20.0% of the PD and 20.9% of the 
UPS cases who had consulted their physician for at least one of their pain symptoms (n = 532 
of the PD and n = 952 of the UPS cases) reported that their pain was specifically attributed to 
nerves or stress by their physician (compare Fig. 1). In contrast, only a few cases (PD: n = 4, 
0.7%; UPS: n = 6, 0.6%) stated that their physician explained their pain by anxiety, panic, or 
depression.  
 
Gender and age differences in lifetime prevalence rates of the pain categories are shown in 
Fig. 3a. Compared to men, women significantly more frequently had PD (females: 17.8% vs. 
males: 7.8%, OR = 2.6, 95% CI: 2.1– 3.2, P < 0.001) and UPS (females: 27.8% vs. males: 
19.6%, OR = 1.6, 95% CI: 1.3–1.9, P < 0.001), but less frequently EPS (females: 29.3% vs. 
males 50.3%, OR = 0.6, 95% CI: 0.5–0.7, P < 0.001). The lifetime prevalence of EPS is 
higher in older age groups both in males (35–49 vs. 18–34 years: OR = 1.4, 95% CI: 1.1– 1.8, 
P = 0.006; 50–65 vs. 18–34 years: OR = 1.9, 95% CI: 1.5–2.5, P < 0.001) and in females (35–
49 vs. 18– 34 years: OR = 1.4, 95% CI: 1.1–1.7, P = 0.008; 50–65 vs. 18–34 years: OR = 1.8, 
95% CI: 1.4–2.2, P < 0.001). In contrast, such increases in lifetime prevalence with higher age 
are not found for PD and UPS (all comparisons not significant with the exception of a higher 
rate for PD in 50–65 vs. 18–34 years old males: OR = 1.8, 95% CI: 1.2– 2.8, P = 0.008).  
 
                                                 
1 For ratios >1: {0 - [1 - (adjusted ratio - 1) / (unadjusted ratio - 1)] x 100}, 
For ratios <1: {1 - [adjusted ratio - 1) / (unadjusted ratio - 1)] x 100}. 
The 12-month prevalence rates for any anxiety disorder and any depressive disorder were 
14.5 and 10.9%, respectively. Age and gender-specific rates are lower, but similar to the ones 
of unexplained pain (Fig. 3b). Relative to males, females more frequently reported an anxiety 
disorder (males: 9.2%, females: 19.8%; OR = 2.4, 95% CI: 2.0–2.9, P < 0.001) and a 
depressive disorder (males: 7.6%, females: 14.2%; OR = 2.0, 95% CI: 1.6–2.5, P < 0.001). 
Similarly, age was unrelated to anxiety disorders in both genders and to depressive disorders 
in males; females of higher age groups had higher rates of depression (35–49 vs. 18–34 years: 
OR = 1.4, 95% CI: 1.03–1.9, P = 0.034; 50–65 vs. 18–34 years: OR = 1.4, 95% CI: 1.02–2.0, 
P = 0.035).  
 
As also shown in Fig. 2, individuals with lifetime PD are frequently comorbid with anxiety 
(31.7%) and depressive (24.5%) disorders in the prior 12-months. Comorbidity with anxiety 
and depressive disorders decreases when the definition of pain is broadened to any 
unexplained pain (anxiety disorder: 24.2%; depressive disorder: 17.8%) and to any significant 
pain (anxiety disorder: 16.5%; depressive disorder: 12.2%).  
 
Overall, 1.9% of the sample reported all three diagnostic categories: lifetime PD as well as 
12-month anxiety, and depressive disorders. This prevalence increases to 3.5 and 4.7% when 
broadening the pain definition to any unexplained pain and any significant pain, respectively.  
 
Associations between pain and specific anxiety and depressive disorders 
 
Using the mutually diagnostic pain categories, consistently higher proportions of 12-month 
rates of specific anxiety and depression diagnoses are found among individuals with PD and 
UPS in comparison to the proportion in the total sample; those without significant pain or 
EPS revealed consistently lower rates (Table 1). Of note, all individuals with GAD reported 
any significant pain with the majority suffering from PD.  
 
Table 2 shows the respective pain associations for the specific depressive and anxiety 
disorders. Starting with a crude model (controlling for age and gender only, upper part of 
Table 2) and using individuals without significant pain as reference, it was observed that not 
only PD (OR range: 3.3–14.8) but also UPS (OR range: 2.4–7.3) were associated with all of 
the specific depressive and anxiety disorders (exception: OR not significant for UPS and 
OCD). Odds ratios for EPS were consistently lower and only few were significant (dysthymia, 
specific phobia, phobia NOS, any anxiety disorder). Using EPS as comparison group, 
significantly stronger relationships to almost all of the anxiety and depressive disorders are 
found for PD and UPS, respectively. Overall, PD is most strongly associated with anxiety and 
depressive disorders as also indicated by significantly greater odds ratios relative to UPS.  
 
We repeated the analyses while additionally controlling for comorbidity between and among 
depressive and anxiety disorders, i.e., the association for any depressive disorder with pain 
was controlled for any comorbid anxiety disorder and the association between for example 
social phobia and pain was controlled for comorbid other anxiety disorders and any comorbid 
depressive disorder (Table 2, middle part). Although there was a consistent drop in the size of 
the odds ratios, most associations remained significant. Using no significant pain symptoms 
as reference group, there were only two attenuated OR in each of the significant pain 
categories (PD: social phobia and OCD, UPS: social phobia and agoraphobia, EPS: dysthymia 
and phobia NOS).  
 
Additionally adjusting for the number of physical disorders in a third step (Table 2, lower 
part), a rather minor drop in the size of the odds ratios was observed. Using no pain as the 
reference, only two more associations were attenuated additionally (PD: agoraphobia, EPS: 
specific phobia). Relative to EPS, unexplained pain (PD and UPS) still revealed significantly 
stronger relationships to almost all of the anxiety and depressive disorders.  
 
As individuals with PD and UPS may also experience explained pain symptoms, we finally 
also controlled for the number of co-occurring EPS. All association remained relatively 
unchanged with the exception that the associations for PD and UPS with major depression 
were attenuated when no PS was used as reference group (not shown in table; results available 
upon request).  
 
In order to investigate reasons for the strong associations between PD and UPS on the one 
hand and anxiety and depressive disorders on the other hand, we first wanted to rule out 
artifactual comorbidity due to misclassification. As stated earlier, only very few of the pain 
cases (PD: n = 4, 0.7%; UPS: n = 6, 0.6%) stated that their physician attributed the pain 
directly to anxiety, panic, or depression. Further, the examination of the temporal order of 
onset revealed that only few comorbid cases reported a same year onset of pain and anxiety 
disorder (PD: n = 11, 6.2%; UPS: n = 15, 6.7%), respectively, pain and depressive disorder 
(PD: n = 10, 7.0%; UPS: n = 16, 9.1%). Pain began at least 1 year prior to depression in the 
majority of cases (PD: n = 107, 72.5%; UPS: n = 105, 66.9%), whereas the onset of comorbid 
anxiety disorder was found to be equally frequently prior to (PD: n = 97, 46.9%; UPS: n = 94, 
38.3%) or after pain onset (PD: n = 94, 46.9%; UPS: n = 134, 55.0%).  
 
A further exploration of the pain–anxiety/depression associations revealed no interaction 
effects with age (as dimensional measure) and only two interactions with gender. Relative to 
no significant pain, the associations between UPS and any depressive disorder (interaction 
with gender: OR = 3.1, 95% CI: 1.3–7.3, P = 0.011) and major depression (interaction with 
gender: OR = 3.4, 95% CI: 1.3–8.9, P = 0.015), respectively, were significantly larger for 
females than for males.  
 
We also examined whether specific pain sites were particularly associated with any anxiety 
and/or depressive disorder. There was no consistent indication for this, as almost all explained 
pain symptoms were associated with any depressive disorder (OR range: 1.3–1.9; exceptions: 
chest pain, painful menstruation, other pain) and any anxiety disorder (OR range: 1.4–1.8; 
exceptions: headache, painful menstruation). This lack of specificity was even more 
pronounced for unexplained pain symptoms with overall higher associations (OR range for 
any depressive disorder: 1.5–2.8; exception: other pain; OR range for any anxiety disorder: 
1.9–4.8; no exceptions).  
 
Finally, we examined whether duration/persistence characteristics were particularly important 
for the strong associations between unexplained pain and any anxiety and depressive disorder. 
Among individuals with PD, but not UPS, self-reports of having experienced pain for a period 
of 6 months, or that their pain bothered most of the time, were indicative of any depressive 
disorder (OR = 1.2, 95% CI: 1.1–1.3, P = 0.001) and any anxiety disorder (OR = 1.2, 95% CI: 
1.1–1.3, P < 0.001) relative to individuals with unexplained pain who did not report this. 
Furthermore, individuals with PD who reported being kept from working or seeing 
friends/relatives for 6 months or more were also more likely to report any depressive disorder 
(OR = 1.2, 95% CI: 1.02–1.3, P = 0.023) and any anxiety disorder OR = 1.2, 95% CI: 1.1–1.3, 
P = 0.003).  
 
Correlates of pain 
 
Table 3 shows measures of self-reported quality of life, disability, health care utilization, and 
substance use by pain group and Table 4 contains their respective associations. All pain 
categories are associated with a decreased physical health-related quality of life, a higher 
number of disability days, increased general practice and specialist health care visits, and 
higher rates of illicit medication/substance use. PD and UPS further revealed a decreased 
mental health-related quality of life and higher rates of harmful alcohol use; PD and EPS 
groups showed an increased number of hospital days and higher rates of daily smoking. 
Overall, there is some evidence for dose-response relationships as indicated by increasing 
ratios from EPS to UPS to PD for most of the correlates.  
 
An exploration into the change of these associations by adjusting for comorbid anxiety or/and 
depressive disorders revealed that all associations in all of the pain groups were decreased as 
indicated by ORs approaching 1.0. Percentages for association change were largest for the 
unexplained pain groups (PD and UPS). Adjusting for anxiety disorders only generally had 
higher effects compared to depressive disorders only for all examined correlates with the 
exception of days in hospital; largest effects were found when adjusting for both anxiety and 
depressive disorders.   
 
 
Discussion 
 
Using a large community sample, the present study examined the differential association of 
specific DSM-IV-defined anxiety and depressive disorders with pain disorder and pain 
symptoms as assessed via standardized diagnostic instrument. Keeping in mind the ongoing 
controversy surrounding the pain classification [35, 49, 56, 75, 84, 86] as well as some 
limitations adjunct to this study (see below), there are two major findings. First, there is a high 
association between pain and both specific anxiety and depressive disorders, with strong 
evidence for a dose-response relationship. Second, although all levels of pain are associated 
with decreased health-related quality of life and increased disability, health care utilization 
and substance use, such adverse functional outcomes are more likely in UPS/PD. Anxiety and 
depressive disorders and their comorbidity account for a substantial part of these adverse 
outcomes, with some indication for differential effects.  
 
Our reported 12-month prevalence rates for anxiety and depressive disorders are in the range 
of other studies [46, 97]. In terms of pain prevalence, given the lifetime assessment, it was not 
unexpected that four out of five individuals reported having experienced any significant pain, 
particularly as our results showed the expected increase in EPS with older age. The lifetime 
prevalence for unexplained pain was similar across all age groups, indirectly indicating a 
stable phenomenon. A direct comparison of our pain rates with other studies is difficult due to 
extensive variance in pain definitions and methods used [e.g., 20, 21, 26, 30, 36, 59, 91]. Our 
findings indicate that almost half of the individuals with significant lifetime pain report at 
least one of their pain symptoms not being (fully) explained by physical/substance-related 
factors (any UPS); overall, 12.7% of the general population met criteria for PD. This is 
consistent with prior research that documented high rates of somatoform pain [30, 36, 53]. 
Together with our findings of decreased health-related quality of life and increased disability, 
help seeking, and substance use among pain sufferers, these high prevalence rates indicate a 
substantial public health and societal burden associated with pain in general and PD and UPS 
in particular.  
 
Our study confirmed the well-known symptomatic relationship between pain and depression 
and anxiety on the DSM-IV diagnostic level for various specific depressive and anxiety 
disorders. PD and UPS, but not EPS, continued to show strong and consistent associations 
with specific anxiety and depressive disorders after adjusting for comorbidity with other 
disorders and physical illnesses. Furthermore, the associations between PD/UPS and specific 
anxiety and depressive disorders also persisted, when co-occurring EPS were controlled. 
These findings suggest a prominent role of unexplained pain in the pain-mental disorder 
association that warrants further research and clinical attention, irrespective of the unknown 
future of such conditions in terms of labelling and diagnosis [compare: 51]. Our findings also 
highlight the importance of the anxiety disorder comorbidity in pain. In line with the few 
available data from community samples [33, 58, 59, 91], the associations between pain and 
anxiety disorders were of equal or greater strength compared to the pain-depression 
associations. Of note, despite no overlap in DSM-IV diagnostic criteria, a particularly high 
(100%) comorbidity rate was found for GAD and pain. As GAD differs from other anxiety 
disorders in various respects, this strong association requires further investigation [11].  
 
Noteworthy, in order to rule out artifactual comorbidity we investigated whether physicians 
attributed the pain explicitly to anxiety or depression, or whether pain and anxiety/depression 
emerged at the same time. None of these explanations accounted sufficiently for our finding 
of high associations between unexplained pain and anxiety and depressive disorders.  
 
Consistent with other research [20, 91], our study also indicates a strong link between pain 
and adverse functional outcomes and health care utilization. Some studies [18, 20, 91] suggest 
that mental disorders such as depression have a significant impact on disability among 
individuals with pain. Our study adds that comorbid anxiety disorders and comorbid 
depressive disorders as well as their comorbidity account for a substantial degree of the 
decreased quality of life, greater impairment in role functioning, disability, health care 
utilization, and substance use among individuals with pain with some indication for 
differential effects. First, the comorbidity with anxiety and/or depressive disorders seems to 
be of greater importance for the adverse correlates in individuals with UPS/PD as compared 
to EPS. Second, there is some indication for a higher relevance of anxiety disorders than 
depressive disorders for the adverse pain outcomes, with the exception of days in hospital. 
Limitations of our study are as follows: first, beyond the general problems associated with 
assessing and categorizing symptoms as „medically (un)explained“ [49, 56, 75], in the current 
study the threshold levels for both clinical significance and absence of medical explanation 
may be perceived as rather low. Second, since no age-of-recency information was available 
for explained pain symptoms, we considered lifetime occurrences of pain, which may be 
subject to recall bias. Adjunct to this, the status of lifetime pain categories during the 12-
month period prior the interview, for which anxiety and depressive disorders have been 
assessed, remained unclear. Third, due to our epidemiological study method, our diagnostic 
categories rely on respondents’ self-report, and thus their perceptions, rather than on a 
medical appraisal/evaluation of pain symptoms. The DIA-X/M-CIDI diagnoses pain disorder 
with imperfect validity.  
 
With these limitations in mind, our results – combined with findings from previous studies – 
have implications for research and practice. Given the high prevalence and association of 
pain, anxiety and depressive disorders, it is crucial to investigate potential causes for these 
relationships in order to develop and test targeted interventions. For the comorbidity between 
pain and depressive disorders, prior research indicates a bi-directional aetiology [52, 78], with 
some indication, that depression is rather a consequence than an antecedent of pain [9, 25]. 
For the pain-anxiety disorder comorbidity, not as much systematic research into the temporal 
order has been performed. Given findings of an earlier incidence of anxiety disorders in 
comparison to depressive disorders [39, 45, 100], it is likely that anxiety disorders, more 
frequently than depressive disorders, occur temporally prior to pain. Although limited by the 
methodological restriction that lifetime information was not available for all the anxiety and 
depressive disorders in the present study, our explorations into the temporal order of onset are 
in line with these assumptions: While depressive disorders occurred temporally secondary to 
pain in the majority of cases, anxiety disorders had their onset about equally frequently prior 
to and after pain. Our cross-sectional, epidemiological study does not allow for conclusions 
on causality. Further research is necessary to study possible direct links between pain and 
anxiety/depression and potential differences in pain aetiology in depression versus anxiety.  
 
Other explanations for the frequent comorbidity of pain and anxiety/depression are 
perpetuating and/or mediating processes and common underlying aetiological/pathogenic 
factors. Pain, anxiety disorders, and depressive disorders all reveal associations with similar 
social and environmental variables (e.g., low socioeconomic status, adverse life experiences) 
[10, 39, 43, 89]. These conditions may also be perpetuated by similar cognitive processes and 
behavioural factors (e.g., catastrophizing, helplessness, fear of pain, pain/anxiety sensitivity, 
avoidance and adverse health behaviours) [6, 9, 17, 44, 63, 71, 78, 88, 92], and possibly imply 
an overlapping genetic and (neuro-) biological (hypothalamic-pituitary-adrenal axis, 
ascending/descending serotonergic/noradrenergic neurotransmitter pathways) vulnerability, as 
has been suggested primarily for pain and depression [9, 12, 16, 17, 52, 67, 78, 79, 88]. Given 
the strong association between pain and anxiety/ depressive disorders and the potential for 
common underlying mechanisms for those associations, it is conceivable that pain symptoms 
may even be an integral part of mental disorders as suggested by some authors in regard to 
depression [e.g., 68, 80]. Our findings indicate that this suggestion may be extended to at least 
some of the anxiety disorders. However, there is also a body of evidence that antidepressants 
have an independent mode of action in depression (antidepressant effect) and pain (analgesic 
effect) [67, 88], indirectly suggesting the presence of separate conditions.  
 
From a clinical perspective, our findings suggest that health professionals should add to their 
awareness of the strong association between pain and a range of anxiety and depressive 
disorders since these conditions may negatively affect illness course and severity [27, 32, 64, 
65], help seeking [10, 20, 29], recognition [8], treatment/referral decisions [42], health care 
costs [29], and treatment outcome [7, 41]. Patients presenting with pain, anxiety, or 
depression should be assessed for the presence of other disorders. Although psychological 
assessment instruments complementing the pain assessment exist [19, 28, 29], patient reports 
of pain are frequently not followed-up with screening questions for anxiety and depression, 
resulting in low treatment rates for the emotional disorders [90, 98]. This is unfortunate in 
light of findings showing that improved depression care is also beneficial for decreasing pain 
and improving quality of life [54]. Similarly, pain is frequently overlooked in mental health 
settings and inadequately considered in treatment [68]. Our findings that the pain-anxiety 
association is at least as strong as the pain-depression association, and that anxiety disorders 
relative to depressive disorders partly account for a greater proportion of variance in adverse 
pain outcomes, call for improved awareness and recognition for both types of mental 
comorbidities. Regarding optimizing treatment, diagnostic versus symptomatic assessment 
has the advantage of clearer therapeutic implications. Both cognitive-behavioural 
interventions and pharmacological treatments are indicated for sufferers of pain and anxiety 
and/or depression [31, 55, 62, 67, 77, 79, 87, 88]. Irrespective of future classification and 
labelling, particular attention should be given to observations or patient’s reports of 
unexplained pain, as its presence is associated with increased mental comorbidity and 
negative functional outcomes. 
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